Which hospitals in China can I purchase Etrasimod-Velsipity?

Itramod (Velsipity) is not yet officially launched in China, nor is it included in medical insurance, so it cannot be purchased directly in most domestic hospitals and pharmacies. This drug is mainly used for the treatment of moderately to severely active ulcerative colitis. It is a new type of oral targeted drug that has the advantages of being taken once a day and easy to use. Since it has not been approved for marketing in the country, patients need to obtain it through specific channels if they need it.

Currently, itrimod may be available in limited supply in some designated hospitals through the Hong Kong-Macao Medical Device Access Policy or the "Guangdong-Hong Kong-Macao Greater Bay Area Mainland Clinically Urgently Needed Drugs" policy. This means that patients in China can only try to apply for use at a few large hospitals associated with the Hong Kong and Macao channels, but cannot freely purchase them in hospitals across the country like regular prescription drugs. Specific supply hospitals and usage qualifications shall be subject to official announcements or actual notifications from hospitals.

In overseas markets, Itramod is already available as the original drug, including European and American versions, with prices per box ranging from approximately RMB 10,000 to RMB 30,000. There are currently no generic drugs, so if patients obtain them through overseas channels, they need to pay attention to the authenticity, transportation safety and storage conditions of the drugs. Purchasing without formal channels involves legal and security risks, so you should choose carefully.

Overall, itramod is still a new drug that is not widely available in China. If patients want to use it, they should first consult their attending doctor to find out whether there are designated hospitals participating in the Hong Kong and Macao channel that can apply. At the same time, purchasing drugs through informal channels should be avoided to ensure drug safety and legal compliance. As the approval progresses in the future, the domestic accessibility and price policies of the drug are expected to be further clarified.

Reference materials:https://www.fda.gov/